I am one of the Biotech Analysts at Jefferies. I would like to welcome the CEO of Tyra Biosciences. We have Todd Harris, and Todd is going to give some slides at the beginning, provide an intro to the company, and then we will go into fireside chat. I would like to turn it over to Todd. Thanks for joining us.
All right. Thanks, Maury, and good morning, everyone. We will be making some forward-looking statements today, so please be advised. I want to talk about focus for Tyra going into 2027. We have been talking about over the last year our dabogratinib 3x3 strategy. Tyra is a precision medicine company focused in the FGFR family with a lead compound that is a first FGFR3 selective oral small molecule inhibitor to make it in the clinic. This is actually a molecule that we made ourselves. It is homegrown through our structure-based drug design approach that we call our SNÅP chemistry platform. We read out some very compelling data this fall in our intermediate-risk NMIBC study. On the back of that, we had a $400 million raise.
We have a balance sheet now of $700 million, where we are going to be prosecuting two of the big indications, two both blockbuster indications in our dabogratinib 3x3 strategy for urothelial carcinoma. This includes the intermediate-risk NMIBC opportunity, a multi-blockbuster opportunity, as well as the upper tract urothelial carcinoma indication, a very high unmet need indication where patients typically lose their kidney. You can expect this year that we are going to be launching our phase III in intermediate-risk NMIBC in 2027, as well as updating our SURF302 data, our phase II data, with longer term safety and efficacy. We will also be reading out our dose selection data for the low-grade upper tract urothelial carcinoma study. We also have a program, another blockbuster indication with this molecule, dabogratinib, in achondroplasia. We will be reading out dose selection data as well in 2027.
I want to start framing a really important part of our story that we believe is underappreciated by investors, urologists, and the market broadly around the size of the opportunity for oral maintenance in urothelial carcinoma. We believe there is an $18 billion-$36 billion total addressable market for an oral therapy. Why do we believe that? It is based off of really three simple things. First, there are roughly 38,000 new patients a year presenting with intermediate-risk NMIBC or low-grade UTUC. Oral maintenance therapy is a therapy that you are going to need to be on that we are studying for at least two years, and potentially patients would want to be on longer to prevent recurrence, and we will talk about that as we get into the market. If you look at pricing, reference pricing in this space, from ADSTILADRIN to INLEXZO, we are talking about $240,000-$480,000 a year pricing.
Multiply those three together and you get this number. It's very, very large. We stand alone as leaders making this market. There are two other companies that are also pursuing this space, and they're the two largest pharmaceutical companies in the world, Eli Lilly and J&J. This is a very important space, and this is very important innovation for patients. Let's talk about the market. I want to begin with the intermediate-risk NMIBC market. Today, the vast majority of patients are actually foregoing a guideline-mandated treatment of intravesical therapy, and instead waiting to recur. Why are they doing that? Because in the intermediate-risk NMIBC setting, the unmet need is that patients will recur, and they will recur quite frequently. Progression is actually a low risk, but the cost and the disruption from procedures is actually the biggest unmet need for these patients.
They would rather forego an effective therapy that requires 6- 30 visits to the urologist with intravesical therapies and simply wait to recur and undergo a surgery under general anesthesia that is TURBT. Patients are voting with their feet today. They do not want the procedures, and they're not taking the procedures for maintenance. When we look at what's driving all of this recurrence, FGFR3 is clearly the driver. This was data shared this year from Dr. Meeks at AUA. What it highlights is that when you do the FGFR3 genotyping, it is the patients that are FGFR3 positive that are recurring most frequently, with a median recurrence-free survival of 16 months versus 40 months if you're FGFR3 negative. If we can suppress FGFR3 continually, we have the opportunity to bend the disease-free survival curve for these patients to potentially prolong the time by which they may recur.
The evidence has already been generated. Initially, J&J did some great work with both TAR-210 oral erdafitinib, that as long as you stay on therapy, the durability of FGFR3 suppression in preventing recurrence is 100%. As soon as patients come off of therapy, we see in the TAR-210 phase II, three out of four recurred within three months. What this tells us is that constant FGFR3 suppression is needed to maintain disease-free survival. When we look at the space and we look at the various approaches to try and maintain disease-free survival, all of the phase III approaches today preceding us have been intravesical therapies. So, these are therapies that require you to go to the office, have the instillation, have a viral vector, or have chemotherapy, or have a pretzel installed.
We already know from the market that patients are choosing not to have these repeat catheterizations to try and maintain disease. Only one of these, TAR-210, is actually targeting FGFR3, which is the main driver of recurrence. Our approach with oral dabogratinib is the only once-a-day oral therapy that could potentially break in and introduce this very attractive oral maintenance market for patients. Now, we believe oral dabogratinib is actually complementary to all of the intravesical and surgical approaches that are starting to emerge. Why do we believe that? Well, when a patient presents with a new tumor or a recurrent tumor, they have options today. Today, they could undergo general anesthesia and a TURBT procedure. They could also get six instillations of Zusduri to ablate that tumor. But what happens next? Well, the patients are now on the path, especially if they're FGFR3 positive, for potential recurrence.
There are a variety of different approaches to induce a better response with TAR-210, ADSTILADRIN, CG Oncology, and others reading out phase III studies in this adjuvant setting. What we've already learned from the market is that over time, patients fatigue from intravesical therapies. We believe dabogratinib is truly complementary to all of these approaches, because whether you start on dabogratinib for ablation, start on it for induction, or start on it after you have an initial induction with some of these intravesical approaches, long-term maintenance can be achieved by taking a once-daily pill to control your disease. This is why all of the patients that are presenting ultimately are eligible patients to go on dabogratinib. Why do we believe we're going to be successful?
With the data that we just read out this fall from our SURF302 study, this was a marker lesion study in the ablative setting. We actually showcased that for patients that had a small single marker lesion left behind, the response rate in three months from taking oral dabogratinib was 100% with a 75% CR rate. The tolerability was exceptional, supporting chronic oral dosing for years. It's on the basis of this that we're now moving into our maintenance, our adjuvant phase III study, aligning with regulators on that approach, which we are intending to be a placebo-controlled study, and taking the 60 mg dose that generated these data into that study. We believe this is a high probability of success phase III. Why do we believe that?
Well, first off, because we have that median recurrence-free survival data shared this year from Dr. Meeks in the FGFR3-positive population, we can project that on placebo, so patients that are opting not for intravesical therapies, that are just waiting to recur, which is where the vast majority of the patients are today, at two years, the disease-free survival is estimated to be at 36%. That means 64% of patients are at risk. We can take the data we just generated on CR rates, PR rates. In the most conservative scenario, we're going to look for a hazard ratio of 0.6. The reality is, if we look at the single marker lesion data we just read out, 100% OR, 75% CR, we're projecting a very attractive disease-free survival curve, one that would generate a very compelling hazard ratio as patients stay on this therapy out for two years.
Let's talk about the market. This is a market creation story. It's driven by two key segments today. The vast majority of patients are not undergoing any maintenance therapy, but there is a small proportion of patients that are at least starting on induction maintenance chemotherapy. That's 30% of the market. In that market, we have an opportunity to win on efficacy and, of course, convenience for those patients that are today choosing to undergo intravesical therapies to try and control their disease. For those that start with instrumentation, we have an opportunity to switch them onto oral dabogratinib for long-term maintenance. We just completed a 150-patient survey testing this profile of oral dabogratinib against the other options for these patients.
These are physicians that are community urologists, and this is important because to get at that community urologist, this is where the vast majority of patients are being treated, not in the academic medical center. The average urologist that we tested here, that we surveyed, treats about 43 patients a year, spends 90% of their time in patient care, and remarkably, 87% of our 150 urologists that we surveyed already has an in-office dispensed pharmacy. We will talk a little bit more about why that is important, but they are generating practice revenue by having their own pharmacy for some of the prostate cancer drugs.
Now, when testing this profile, the vast majority of urologists said, "We would love to start with oral dabogratinib." Even for those that start on a device, TAR-210 or some intravesical approach, because of the attractiveness of an oral, fewer repeat catheterizations, a less invasive experience for their patients, we anticipate that oral dabogratinib could be used both initially or even after or complementary to initiating patients on, say, TAR-210 for ablation and even initial induction. Let us talk about the in-office dispense pharmacy. This is very important. It is an evolution over the last 15 years due to the prostate cancer drugs like XTANDI. Physicians have learned that by setting up their own in-office dispense pharmacy, they can share in the spread of the revenue generated from an oral drug, and it has become a major driver of their practice. This is old data, 2021.
If you fast-forward to today, 2026, these community urologists, most of them are making 50% of their practice revenue from the spread they get on prescribing XTANDI, ORGOVYX, Erleada, the prostate cancer drugs. It is a major driver of the economics for the practice or for the economics of the private equity groups that own many of these practices. Over the next couple years, XTANDI and some of the other oral prostate cancer drugs are going to go off patent. This will generate a giant hole in the practice revenue for many urologists. It is for this reason that when we go out and talk about oral dabogratinib, the opportunity for the first time to bring an oral into bladder cancer, we see incredible enthusiasm from urologists in being able to replace this revenue stream that is essentially about to go off patent, and hit their practice revenue.
It aligns with the patient, it aligns with the urologist, it aligns with the private equity groups or the owners of the practices as well, to really look for this drug ultimately to be successful for their patients. Now, the big story here is the market creation in the 70% of patients today that are opting to undergo no intravesical therapies. This is a major segment of the market that is untapped. An oral maintenance therapy for the first time has the ability to take these patients off the sidelines, give them a once-daily pill that would be like taking a vitamin, and allow them to control their disease in the convenience of their own home and avoid the repeat surgeries and the repeat catheterizations that they have to face today. We did a 50-patient survey.
Remarkably, when we asked patients about the dabogratinib target product profile, the number one thing they love about this is the greater privacy, the ability to control their disease in the privacy of their own home, not have to ask their son or their daughter or their friend to drive them to the urologist 30 times a year, six times over six weeks. Reducing the pain, the discomfort, the awkwardness of exposing yourself in this urologist's office are all major elements of what these patients love about an oral maintenance approach. Even if patients still need to go in every quarter to get scoped, to evaluate their tumor stage, we find that patients find the attractiveness of an oral 82% as being very large or large. That is the intermediate-risk NMIBC.
It is by far and away the largest market we will pursue in our dabogratinib 3x3 strategy with oral dabogratinib. There is also a very attractive, rarer disease in upper tract urothelial carcinoma, and a registration path that will probably get us to market the fastest. This is a disease where the urothelial lining in the ureters and the kidney gets one of these low-grade FGFR3-driven tumors. It is about 3,000 patients a year. The standard of care typically results in a patient losing one and sometimes both of their kidneys. These are already elderly patients. Many of them already have renal insufficiency. Removing the kidney is actually the easiest thing that the urologist does in treating this disease. The much more challenging thing is trying to ablate these tumors with a device like this, a ureteroscope.
We find that the challenges associated with this procedure are so high that most patients are going to recur relatively quickly, and it is going to lead to repeat surgical interventions trying to control this disease. When we tell urologists about oral dabogratinib for UTUC, within about five seconds, they understand it, they want to be on our studies, they want to use it. We were pleased to read out the first patient that went on our study this fall. What we highlight here is this is a patient with all of the typical comorbidities you might expect. Type 2 diabetes, they had undergone three fulgurations, they had undergone Jelmyto. Patient presented with a 5 mm low-grade lesion. Three months later, after taking dabogratinib once a day, they had a complete response. They are continuing on therapy, and they had no AEs.
This is like taking a pill, a multivitamin every morning, having your tumor disappear, and having your tumor-free status maintained. This is the holy grail that patients are seeking in this indication. We have an opportunity to read out our dose selection data, a 60 mg dose, that was the dose that this patient was on, an 80 mg dose that we are testing as well, this next year, speak to the FDA, and then within this study, expand the potential pivotal portion for registrational intent. UroGen was able to, with 70 patients, to get a full approval in this indication with a single-arm study, which is the path we anticipate we too can take, which is why we anticipate this will likely be a very rapid path to market and the first indication that we commercialize with dabogratinib.
We've talked about a giant and attractive market, huge unmet need in the urothelial franchise, which we will be targeting with our dabogratinib 3x3 strategy and dabogratinib. There's also a very large opportunity in growth conditions, starting with the tip of the iceberg, achondroplasia. These are FGFR3, the same target-driven short stature conditions. It's not just the billion-dollar market we see in achondroplasia, but it's also the much broader market of other short stature conditions where FGFR3 is a key driver, and where targeting FGFR3 can really open up the market quite extensively. These include things like idiopathic short stature and other short stature conditions, where by targeting FGFR3 with a once-daily oral, we have an opportunity to get best-in-class activity and efficacy. 2027's going to be a catalyst-rich year across all of these programs for Tyra.
We're certainly well-financed at this point to pursue all of our urothelial indications through registration, through an NDA, and we look forward to reading out these data as we get into the next year. With the remaining time, Maury, happy to take some questions.
Come on up, and I'll sit over here.
Okay. Yeah, thanks, Todd. I think that was a great overview and highlights the unmet need for these different disease settings. Maybe for NMIBC, if you just want to talk about next steps for your data update, and you talked about durability, having patients stay on therapy for many years. What are you seeing so far in your phase II data for durability?
Yeah, look, the expectations were set from the early work done by J&J that as long as you stay on drug, CRs are maintained, and even if you see a PR, you can see that convert to CR. We're seeing all of that on the study. We're very encouraged. We will have an update on durability, both for safety and tolerability, as we get into next year. I think the most important milestone will be the kickoff of that phase III.
Maybe for data, I guess, could there be a couple updates next year? How can investors get a sense of what the cadence of data for NMIBC could look like?
Yeah, I mean, we're going to follow the data really to make that determination. We want to be able to provide a fulsome update around the durability of both. So yeah, as we get into 2027, it could be a single update, but it could be multiple updates. As we get close to having that data, we'll certainly guide with more detail when that date would be.
And for getting alignment for the phase III study with FDA, what are you looking for there? Talk about the control arm, I guess the DFS definition, treatment duration, follow-up, and the types of patients that you enroll.
Yeah. I mean, for the most part, we're very confident around the potential design and alignment. The two key questions we want to get real clear guidance and alignment around, one is the placebo control. We've noted that other sponsors have observation as a control arm in their studies, so we think that should be acceptable. And the other piece is looking at the potential path for an ablative indication, not just adjuvant. And we noted that a single-arm study was sufficient for approval with Zusduri, so understanding how the FDA is thinking about that is important to us as well.
Could that potentially move in front of the adjuvant as far as prioritization goes?
Adjuvant will always be the priority because, as we talked about, the oral maintenance market is absolutely where the unmet need sits today.
Yeah.
If you could use an oral drug to ablate, great. There's other options. It's really that adjuvant study, the oral maintenance, that's going to be the prime indication, the prime study where the vast majority of the use of this product would be.
PIVOT-006 took about three years. Would you expect the same for your study too, or would you be able to accelerate timelines there?
It's a great question. We certainly will look to accelerate. The ways that I think we could accelerate is because the FGFR3-selected population is likely to have far more events because of that high rate of recurrence. That certainly can help us speed. We think that this is going to be a very attractive sell for patients to go on an oral therapy in a study, so that could also speed our recruitment as well.
Got it. Okay. When are you going to get that feedback for the phase III design from FDA?
Yeah, we expect to have all the regulatory bodies, so this includes Europe, PMDA Japan, and U.S., going into early next year, and we will incorporate that for the phase III submission.
Okay. Maybe a couple questions on UTUC. You have a competitor out there with Jelmyto that has shown some good CR data there. You have kind of highlighted the benefits of having an oral approach for this setting. For having an oral, what CR and durability would make dabogratinib clearly differentiated rather than just more convenient?
Yeah. Look, I think, again, I think this is complementary more than competitive. When you go on Jelmyto, you might get a 50% CR rate, but then you are going to see this durability that is probably only about 50%. So by the end of the year, only about 30% of patients are benefiting. So adding oral maintenance to that, of course, could be very compelling. We are, of course, studying this with both the ablative potential and the maintenance potential in this single-arm study. So any CR rate, 30%+, we think is sufficient for approval. We think we will get use, physicians tell us with that, any CR rate will get use in all their patients, because it is such a more convenient option before they have to look at the other options.
We think that is really sort of the bar is a pretty low CR rate will still get us there.
Got it. I know you had the slide on the design a little bit earlier, but for the SURF303 study, could you move directly into a registrational study there in the current protocol, or how would that
That is exactly what Jelmyto did. At UroGen's ODAC, FDA reiterated that a single-arm study is appropriate in this indication, so we do believe that we could use the expansion portion for registrational intent.
Got it. What would FDA want to see on durability there on the lower bound confidence interval, and has any threshold been discussed with FDA at this point? Is Jelmyto the main precedent?
Yeah, I would not highlight any thresholds. Jelmyto is a good precedent. The primary, we believe, can be an initial CR. We believe secondary endpoints that include durability are also important to highlighting the value of the drug.
With 10 - 15 patients per dose in your study, what would constitute a clear 60 mg versus 80 mg dose selection signal across CR, durability, exposure response, and tolerability?
Yeah, I think this is pretty simple. If the efficacy is truly comparable between the two doses, we would use the lower dose. We see some preference for the higher dose for efficacy, then I think that would, barring any major safety signals at the 80 mg dose, then we could lean in there. The nice thing too is we could think about induction and maintenance separately here as well, where maybe use a higher dose for ablation and then switch to lower doses for maintenance. That could be a great way to manage these patients. So we'll be able to look at the data and evaluate if that's a dosing scheme we want to use as well.
Got it. Maybe question on achondroplasia against infigratinib's phase III high velocity and proportionality results. What numerical profile would dabogratinib need to justify adoption as a later entrant, and what's your base case and best case view here?
You want to talk about the market research here on this?
Yeah.
Yep.
Yeah, we've done some market research, and even a half centimeter improvement over the existing therapies would drive meaningful share. Obviously, we're looking to beat that and try to shoot for one, but even a half is very, very meaningful in this market because half over six years would be 3 cm.
What's the best case expectation that you could achieve?
Well, I think we don't want to overshoot the mark, but I think anything from the 7 cm- 8 cm is just an excellent case that probably can truly fulfill all of the unmet need.
Well, I think we're out of time, so thanks so much for joining us today.
Thanks, Maury.